metoprolol has been researched along with Essential Hypertension in 5 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Essential Hypertension: Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "A total of 261 healthy individuals and 261 essential hypertension patients treated with metoprolol for 12 weeks were enrolled." | 3.88 | The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk. ( Chen, L; Deng, M; Wu, D; Xiao, T; Xie, S, 2018) |
| "Chinese patients with essential hypertension were treated with the β-blocker metoprolol and followed up for 12 weeks." | 3.81 | Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. ( Deng, M; Guo, X; Huang, X; Li, G; Song, W; Wu, D; Wu, S; Wu, Z; Xu, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 1 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Chen, L | 2 |
| Xiao, T | 1 |
| Xie, S | 1 |
| Deng, M | 2 |
| Wu, D | 2 |
| Mehanna, M | 1 |
| Wang, Z | 1 |
| Gong, Y | 1 |
| McDonough, CW | 1 |
| Beitelshees, AL | 1 |
| Gums, JG | 1 |
| Chapman, AB | 1 |
| Schwartz, GL | 1 |
| Bailey, KR | 1 |
| Johnson, JA | 1 |
| Turner, ST | 1 |
| Cooper-DeHoff, RM | 1 |
| Fici, F | 1 |
| Celik, T | 1 |
| Balta, S | 1 |
| Iyisoy, A | 1 |
| Unlu, M | 1 |
| Demitkol, S | 1 |
| Yaman, H | 1 |
| Brambilla, G | 1 |
| Kardesoglu, E | 1 |
| Kilic, S | 1 |
| Yokusoglu, M | 1 |
| Grassi, G | 1 |
| Li, G | 1 |
| Song, W | 1 |
| Huang, X | 1 |
| Guo, X | 1 |
| Wu, Z | 1 |
| Wu, S | 1 |
| Xu, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses 2[NCT01203852] | Phase 4 | 839 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Genetic Epidemiology of Responses to Antihypertensives[NCT00005520] | 1,200 participants (Actual) | Observational | 1997-02-28 | Completed | |||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in glucose after treatment with study medication (NCT01203852)
Timeframe: after 6-8 weeks treatment
| Intervention | mg/dL (Mean) | |
|---|---|---|
| glucose response to metoprolol (n=365) | glucose response to chlorthalidone (n=318) | |
| Adverse Metabolic Effects | 1.02 | 5.12 |
Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment (NCT01203852)
Timeframe: after 6-8 weeks of treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| diastolic blood pressure response | systolic blood pressure response | |
| Chlorthalidone Only | -7.68 | -13.65 |
| Metoprolol + Chlorthalidone | -7.56 | -11.70 |
| Metorprolol Only | -7.97 | -7.45 |
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
2 trials available for metoprolol and Essential Hypertension
| Article | Year |
|---|---|
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension.
Topics: Adult; Antihypertensive Agents; Benzopyrans; Blood Pressure; Double-Blind Method; Erythrocyte Indice | 2013 |
3 other studies available for metoprolol and Essential Hypertension
| Article | Year |
|---|---|
The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Case-Control Studies; Cytochrome P-450 CYP2D6; Dyslip | 2018 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; China; Cytochrome | 2015 |